Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
about
Therapeutic Drug Monitoring of Posaconazole: an UpdateFundament and Prerequisites for the Application of an Antifungal TDM ServicePopulation pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosisUnderstanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Antifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis.Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis.A retrospective analysis of patient-specific factors on voriconazole clearance.Screening of the central nervous system in children with invasive pulmonary aspergillosis.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach.Azole antifungals: 35 years of invasive fungal infection management.Systemic Antifungal Agents: Current Status and Projected Future Developments.In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.The role of the multidisciplinary team in antifungal stewardship.Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: Trough serum concentrations in relation to outcome.In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia.Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient VariabilityTherapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment.Effective treatment of invasive Aspergillus fumigatus infection using combinations of topical and systemic antifungals in a severely burned patient.Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection.Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
P2860
Q26746016-90BF869A-203B-4D39-91D3-446A4711A36FQ28085352-1029ECEE-1268-458B-BD0C-8CF294A83FF6Q34020402-84594B86-5A89-458B-96CD-8DE892FCA73BQ34596750-9410A92D-2BB5-4565-9FCF-A9043AF5CD63Q35076830-2FB4F148-1AD3-4390-911C-B0D665EC16A4Q35105949-C2212927-744D-46CE-9298-D0CCC3F3BD0BQ35136368-C63CD397-934E-4E95-A0D4-1917504390F9Q35689788-AD1E9661-2529-447B-91F4-0B79DA9832E1Q36810454-1F6618D9-89A2-4B5D-AAD5-AF358A2E9B19Q37631540-C74AFF83-F314-4E99-AB9E-FAC942AAED66Q38285488-49F843C7-FB1C-41A4-B7A6-B798F0641095Q38362057-92CFC581-4C81-4797-B56C-3720FBF0DFF1Q38406393-AD58ABB5-2FBD-4CE0-BC03-13C7CF15A4D5Q38796140-022E7795-CE27-4A4F-B838-D6169DAB90F1Q40248126-AD0AE589-8A61-42B6-9782-2BA81A98B650Q40438373-6726397C-0C89-4989-8155-6F33D3ECEA27Q40762430-5AF1F07C-22CC-4CA5-AF47-A4FA59699003Q41282603-B2D88C32-FB1B-453D-A6BF-B47AF29E32C9Q41991703-E3DD6C79-D9DF-42A5-A50B-D2724A7C35A5Q42101900-B4DF1A7E-DBDF-4A5B-B451-840F91A13386Q42201729-4DF1DAEB-36CF-47AA-AF9E-EC6B2A9F5013Q42563983-493744F5-7DD5-45E4-9A04-69242E0396DDQ45199703-FBC31934-D678-41BE-BB59-E9FB364D20D7Q50094753-31DAEDE7-CAF2-4788-8D93-496AEB5AEBB9Q51631938-E408E756-A404-4523-8A55-B5F1369B1FEDQ52777337-DD168E41-9716-4E0D-83DB-B1DC8A7AF2E8Q53087320-B2B64488-9178-4456-87AE-B7E003B3C0FEQ54214603-F924D281-5AAE-41B8-8FFC-E6D547FA6904
P2860
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
@en
type
label
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
@en
prefLabel
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
@en
P2860
P50
P1476
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis
@en
P2093
Roger J M Brüggemann
P2860
P304
P356
10.1586/14787210.2013.826989
P577
2013-09-01T00:00:00Z